Systems Biology and Drug Screening

Conventional drug design mostly uses the ligand and structure-based approaches (Prathipati and Mizuguchi, 2015). With the advancement in functional genomics and the availability of high-throughput (HTP) data, information on interactive molecular networks can be used to analyze the efficacy and toxicity of various drugs from a more comprehensive view.

High content screens with systems biology analyses may help detect the cellular changes in details (Dunn et al., 2010). Transcriptomic and proteomic profiling would enable the description of the cellular alterations related to diseases and drug responses. Libraries can be constructed for not only small molecules, but also the molecular pathways and networks to facilitate drug screening and design.

Novel systems biology methods based on multiple platforms and various sources with multi-dimensional analyses put emphasis on the cellular networks and relationships among potential drug components.

References:

Dunn DA, Apanovitch D, Follettie M, He T, Ryan T. Taking a systems approach to the identification of novel therapeutic targets and biomarkers. Curr Pharm Biotechnol. 2010 Nov;11(7):721-34.

Prathipati P, Mizuguchi K. Systems biology approaches to a rational drug discovery paradigm. Curr Top Med Chem. 2015 Aug 26.

This entry was posted in Systems Biology and tagged , , , , , , , , , . Bookmark the permalink.

Leave a Reply